Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COMT | P21964 | 5/20 | 0.40 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.32 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.32 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.31 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.31 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.30 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1686711 | 0.90 | COMT (0.38) | COMTSRD5A2TEAD4LTB4RLTB4R2 | |
| SCHEMBL9172538 | 0.86 | IDO1 (0.30) | — | |
| SCHEMBL1686843 | 0.86 | COMT (0.41) | COMTSRD5A2TEAD4 | |
| SCHEMBL9177042 | 0.84 | IDO1 (0.31) | — | |
| SCHEMBL1686852 | 0.84 | COMT (0.40) | COMTLTB4RLTB4R2 | |
| SCHEMBL9366982 | 0.82 | COMT (0.38) | COMTSRD5A2TEAD4LTB4RLTB4R2 | |
| SCHEMBL9174630 | 0.81 | CASP3 (0.39) | — | |
| SCHEMBL9409803 | 0.81 | LTB4R (0.31) | LTB4RLTB4R2 | |
| SCHEMBL9370311 | 0.81 | COMT (0.38) | COMTSRD5A2LTB4RLTB4R2 | |
| SCHEMBL9366427 | 0.80 | COMT (0.36) | COMTSRD5A2LTB4RLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105777464-B | Hydroxamic acid derivative and preparation method and application thereof | 中国科学院上海药物研究所 | 2020-09-29 | — | — | CN | disclosed |
| EP-2124942-B1 | Combination medicaments for treating bacterial infections | BASILEA PHARMACEUTICA AG (CH) | 2016-04-27 | — | — | EP | disclosed |
| US-20150148326-A1 | Monobactams | PFIZER (US) | 2015-05-28 | — | — | US | disclosed |
| US-20150148326-A1 | Monobactams | PFIZER (US) | 2015-05-28 | — | — | US | disclosed |
| EP-2646436-B1 | MONOBACTAMS | PFIZER (US) | 2015-05-27 | — | — | EP | disclosed |
| US-20130252935-A1 | Monobactams | PFIZER INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130252935-A1 | Monobactams | PFIZER INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20120302542-A1 | MONOBACTAMS | PFIZER INC | 2012-11-29 | — | — | US | disclosed |
| US-20120302542-A1 | MONOBACTAMS | PFIZER INC | 2012-11-29 | — | — | US | disclosed |
| WO-2012073138-A1 | MONOBACTAMS | PFIZER INC. (US) | 2012-06-07 | — | — | WO | disclosed |
| EP-1322648-B1 | 3-(HETEROARYL ACETAMIDO)-2-OXO-AZETIDINE-1-SULFONIC ACIDS DERIVATIVES AS ANTIBACTERIAL AGENTS | PANTHERIX LTD (GB) | 2005-06-29 | — | — | EP | disclosed |
| US-20040019203-A1 | 3-(Heteroaryl acetamido)-2-oxo-azetidine-1-sulfonic acids derivatives as antibacterial agents | REMPEX PHARMACEUTICALS, INC. | 2004-01-29 | — | — | US | disclosed |
| EP-1322648-A1 | 3-(HETEROARYL ACETAMIDO)-2-OXO-AZETIDINE-1-SULFONIC ACIDS DERIVATIVES AS ANTIBACTERIAL AGENTS | Pantherix Limited (GB) | 2003-07-02 | — | — | EP | disclosed |
| EP-0979229-B1 | 2-OXO-1-AZETIDINE SULFONIC ACID DERIVATIVES AS POTENT BETA-LACTAMASE INHIBITORS | NAEJA PHARMACEUTICAL INC (CA) | 2002-10-23 | — | — | EP | disclosed |
| WO-2002022613-A1 | 3-(HETEROARYL ACETAMIDO)-2-OXO-AZETIDINE-1-SULFONIC ACIDS DERIVATIVES AS ANTIBACTERIAL AGENTS | PANTHERIX LIMITED (GB) | 2002-03-21 | — | — | WO | disclosed |
| US-5888998-A | INCREASE EFFECTIVENESS OF B-LACTAM ANTIBIOTICS | SYNPHAR LABORATORIES, INC. (CA) | 1999-03-30 | — | — | US | disclosed |
| EP-0251299-B1 | Cephalosporin compounds, processes for their preparation and antibacterial agents | KAKEN PHARMA CO LTD (JP) | 1994-08-31 | — | — | EP | disclosed |
| US-4883879-A | CHEMICAL INTERMEDIATES | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 1989-11-28 | — | — | US | disclosed |
| US-4822786-A | Cephalosporin compounds, and antibacterial agents | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 1989-04-18 | — | — | US | disclosed |
| EP-0251299-A2 | Cephalosporin compounds, processes for their preparation and antibacterial agents | Kaken Pharmaceutical Co., Ltd. (JP) | 1988-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252935-A1 | Monobactams | MGAM, MGAM2, BPGM | COMT 1386/4885SRD5A2 4450/4885TEAD4 3932/4885 |
| US-20150148326-A1 | Monobactams | MGAM, MGAM2, BPGM | COMT 1386/4885SRD5A2 4450/4885TEAD4 3932/4885 |
| US-20040019203-A1 | 3-(Heteroaryl acetamido)-2-oxo-azetidine-1-sulfonic acids derivatives as antibacterial agents | Q6ZSR9, SOS1, SOS2 | COMT 3882/4885SRD5A2 761/4885TEAD4 3308/4885 |
| US-20120302542-A1 | MONOBACTAMS | MGAM, MGAM2, BPGM | COMT 1386/4885SRD5A2 4450/4885TEAD4 3932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.